T2 Biosystems (TTOO)
(Delayed Data from NSDQ)
$4.39 USD
+0.70 (18.81%)
Updated May 13, 2024 04:00 PM ET
After-Market: $4.42 +0.03 (0.68%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMT2 Biosystems (TTOO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.18 | $5.35 | $3.00 | 12.97% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for T2 Biosystems comes to $4.18. The forecasts range from a low of $3.00 to a high of $5.35. The average price target represents an increase of 12.97% from the last closing price of $3.70.
Analyst Price Targets (2 )
Broker Rating
T2 Biosystems currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 3.00 a month ago based on two recommendations.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/29/2024 | Canaccord Genuity | Kyle Mikson | Hold | Hold |
7/13/2023 | Alliance Global Partners | Benjamin Haynor | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 2 |
Average Target Price | $4.18 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 100 of 252 |
Current Quarter EPS Est: | NA |